Triple-negative breast cancer (TNBC), defined as nonexpression of estrogen receptor (ER) and progesterone receptor and no amplification or overexpression of human epidermal growth factor receptor 2 (HER2), accounts for 10–20% of breast cancers. Here, ESR1 is linked to triple-negative breast carcinoma.